fluconazole has been researched along with saquinavir in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egbert, M; Keserű, GM; Vajda, S; Whitty, A | 1 |
| Zingman, BS | 1 |
| Conde, C; Diz, J; Gonzalez-Mediero, G; Rodriguez De Lope, A; Santiago, P; Seijo Martinez, M; Visvesvara, GS | 1 |
| Beijnen, JH; Burger, DM; Crommentuyn, KM; Hoetelmans, RM; Koks, CH; Koopmans, PP; Mathôt, RA; Meenhorst, PL; Mulder, JW | 1 |
| Gouda, H; Handa, K; Hirono, S; Nakagome, I; Yamaotsu, N | 1 |
| Elgammal, Y; Salama, EA; Seleem, MN | 1 |
1 review(s) available for fluconazole and saquinavir
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for fluconazole and saquinavir
| Article | Year |
|---|---|
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Biological Availability; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Fluconazole; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Ritonavir; Saquinavir; Time Factors | 2001 |
14 other study(ies) available for fluconazole and saquinavir
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Why Some Targets Benefit from beyond Rule of Five Drugs.
Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding | 2019 |
Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Antiviral Agents; Candidiasis, Oral; Didanosine; Fluconazole; HIV Protease Inhibitors; Humans; Isoquinolines; Male; Quinolines; Saquinavir | 1996 |
Granulomatous amebic encephalitis in a patient with AIDS: isolation of acanthamoeba sp. Group II from brain tissue and successful treatment with sulfadiazine and fluconazole.
Topics: Acanthamoeba; Acquired Immunodeficiency Syndrome; Adult; Amebiasis; Animals; Antibiotic Prophylaxis; Antiretroviral Therapy, Highly Active; Biopsy; Brain; Brain Abscess; Didanosine; Fluconazole; Humans; Male; Saquinavir; Sulfadiazine; Trimethoprim, Sulfamethoxazole Drug Combination | 2000 |
Three-dimensional quantitative structure-activity relationship analysis of inhibitors of human and rat cytochrome P4503A enzymes.
Topics: Animals; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Fluconazole; Fluvoxamine; Humans; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Docking Simulation; Quantitative Structure-Activity Relationship; Rats; Ritonavir; Saquinavir | 2013 |
Saquinavir potentiates itraconazole's antifungal activity against multidrug-resistant Candida auris in vitro andin vivo.
Topics: Animals; Antifungal Agents; Azoles; Candida; Candida auris; Fluconazole; Itraconazole; Mice; Microbial Sensitivity Tests; Saquinavir | 2023 |